Institute Report
America's Greatness in the Biopharmaceutical Sector
Sustaining U.S. Leadership
May 15, 2025
Download

The U.S. biopharmaceuticals sector — the collection of companies that discover, develop, and commercialize therapeutics and medicines for patients in the U.S. and around the world — contributes to the U.S. economy, healthcare system, and society through its focus on innovation and technology, while concurrently reducing mortality and morbidity from illness. The sector has developed an eco-system that combines a multitude of scientific discovery platforms with robust dissemination of information, intellectual property protection, a global talent pool, funding markets that provide liquidity, and a relatively transparent and responsive regulatory regime.

This eco-system has delivered enormous value and has been a major net contributor to the U.S.; however, there are aspects of the current system that can be improved, and competition from other parts of the world is increasing. Addressing these issues — while maintaining or increasing the strengths of the existing eco-system — can contribute to the broader goals of enhancing America’s global leadership and at the same time increase the contribution of this critical strategic sector.

This Perspective from the IQVIA Institute for Human Data Science is intended to contribute to the current discussion around several Executive Orders and policy proposals being discussed or implemented by the current U.S. Administration. It draws on recent research by the IQVIA Institute and others to bring a balanced and objective view of how the goals of the administration can be best supported by a vital and sustained biopharmaceutical sector.

This Perspective is produced as a public service without external funding or support.

Related solutions

Contact Us